Physician profile
Saji Eapen
NPI 1003804204
$14,842.31
in general payments reported to CMS, 2019-2025
75 companies · $1,544 in 2025
The $1,544 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,295 · 2020: $1,913 · 2021: $3,003 · 2022: $2,163 · 2023: $2,091 · 2024: $1,833 · 2025: $1,544.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,266 · Education: $202.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,265.77 |
| Education | $202.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Epizyme, INC. | $1,381.40 | 2020-2022 | |
| Merck Sharp & Dohme LLC | $957.43 | 2019-2025 | Keytruda, Lynparza, Welireg |
| Novartis Pharmaceuticals Corporation | $891.58 | 2019-2025 | |
| Amgen INC. | $859.09 | 2019-2023 | Blincyto, Kyprolis |
| Astrazeneca Pharmaceuticals LP | $790.07 | 2019-2025 | Calquence, Enhertu, Imfinzi |
| E.R. Squibb & Sons, L.L.C. | $714.66 | 2019-2025 | Opdivo, Opdualag, Pomalyst |
| Celgene Corporation | $673.48 | 2019-2025 | Reblozyl, Pomalyst |
| Pfizer INC. | $649.25 | 2019-2025 | |
| Janssen Biotech, INC. | $640.67 | 2019-2025 | Darzalex, Tecvayli, Erleada |
| Glaxosmithkline, LLC. | $487.63 | 2020-2025 | Ojjaara, Jemperli, Zejula |
| Gilead Sciences, INC. | $470.15 | 2019-2025 | Trodelvy |
| Daiichi Sankyo INC. | $406.69 | 2020-2025 | Enhertu, Injectafer, Datroway |
| Genentech USA, INC. | $400.51 | 2019-2024 | Perjeta, Phesgo, Kadcyla |
| Regeneron Healthcare Solutions, INC. | $310.34 | 2019-2025 | Libtayo |
| Abbvie INC. | $307.04 | 2021-2025 | Venclexta |
Show all 72 companies
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Saji Eapen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.